10.2 Communicating benefits, limits, and safety boundaries Within the current evidence and regulatory framework, GLP-1RA management should be proceduralized using explicit entry points, target goals, and exit rules to minimize uncertainty and risk spillover: The triple-question pre-prescription assessment: before prescribing, clinicians should systematically address three questions: (i) What is the patients metabolic risk tier (BMI/IR, MASLD, glycemic status, etc.)
Your attorney requests evidence during the discovery process of your Ozempic case
We plan that step with you
For instance, in November 2023, Lilly Canada, a medicine company, announced that Mounjaro (tirzepatide) is now available in Canada